Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors

15 Jun 2011

Abstract excerpt

ErbB2 tyrosine kinase inhibitors (TKI) block tyrosine autophosphorylation and activation of the full-length transmembrane ErbB2 receptor (p185(ErbB2)). In addition to p185(ErbB2), truncated forms of ErbB2 exist in breast cancer cell lines and clinical tumors. The contribution of these truncated forms, specifically those expressed in tumor cell nuclei, to the development of therapeutic resistance to ErbB2 TKIs has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21673090
DOI: 10.1158/1535-7163.mct-10-0991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase InhibitorsPMID 21673090Read ↗

Clinical evaluation of BCL-2/X<sub>L</sub> levels pre- and post- HER2-targeted therapySemantic proximity Read ↗

Mechanisms of lapatinib resistance in HER2-driven breast cancer.Semantic proximity Read ↗

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Semantic proximity Read ↗

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapySemantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.Semantic proximity Read ↗

PP2A inhibition overcomes acquired resistance to HER2 targeted therapySemantic proximity Read ↗

Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA GenesSemantic proximity Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.Semantic proximity Read ↗

Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.Semantic proximity Read ↗

Interaction between Her2 and Beclin-1 Proteins Underlies a New Mechanism of Reciprocal RegulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.